Brief Report
Vivek Naranbhai(Centre for Human Genetics), Adrian V. S. Hill(Jenner Institute), Clemensia Nakabaiito(Johns Hopkins University), Lynda Stranix‐Chibanda(University of Zimbabwe), M E Fowler(Centre for Human Genetics), Karim Manji(Muhimbili University of Health and Allied Sciences), Lynda Emel(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Philippa Musoke(Centers for Disease Control and Prevention), Helen A. Fletcher(London School of Hygiene & Tropical Medicine), Paul Richardson(University of Liverpool), Moreen Kamateeka(Johns Hopkins University), Helen McShane(University of Oxford), Kathleen George(Family Health International 360), P. Andrew(Family Health International 360), Tsungai Chipato(University of Zimbabwe-University of California San Francisco), Hoosen Coovadia(University of KwaZulu-Natal), Dhayendre Moodley(Centre for the AIDS Programme of Research in South Africa)
Cited by 43
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
|Nature Medicine|2020|643
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
|New England Journal of Medicine|2021|557